Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 266
Filter
2.
J Med Chem ; 67(8): 6238-6252, 2024 Apr 25.
Article in English | MEDLINE | ID: mdl-38598688

ABSTRACT

Thirty-one novel albaconazole derivatives were designed and synthesized based on our previous work. All compounds exhibited potent in vitro antifungal activities against seven pathogenic fungi. Among them, tetrazole compound D2 was the most potent antifungal with MIC values of <0.008, <0.008, and 2 µg/mL against Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus, respectively, the three most common and critical priority pathogenic fungi. In addition, compound D2 also exhibited potent activity against fluconazole-resistant C. auris isolates. Notably, compound D2 showed a lower inhibitory activity in vitro against human CYP450 enzymes as well as a lower inhibitory effect on the hERG K+ channel, indicating a low risk of drug-drug interactions and QT prolongation. Moreover, with improved pharmacokinetic profiles, compound D2 showed better in vivo efficacy than albaconazole at reducing fungal burden and extending the survival of C. albicans-infected mice. Taken together, compound D2 will be further investigated as a promising candidate.


Subject(s)
Antifungal Agents , Candida albicans , Cryptococcus neoformans , Microbial Sensitivity Tests , Tetrazoles , Antifungal Agents/pharmacology , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Antifungal Agents/therapeutic use , Tetrazoles/pharmacology , Tetrazoles/chemistry , Tetrazoles/chemical synthesis , Tetrazoles/pharmacokinetics , Tetrazoles/therapeutic use , Animals , Humans , Candida albicans/drug effects , Mice , Cryptococcus neoformans/drug effects , Structure-Activity Relationship , Aspergillus fumigatus/drug effects , Drug Discovery , Drug Resistance, Fungal/drug effects , Candidiasis/drug therapy , Cytochrome P-450 Enzyme Inhibitors/pharmacology , Cytochrome P-450 Enzyme Inhibitors/chemical synthesis , Cytochrome P-450 Enzyme Inhibitors/chemistry , Cytochrome P-450 Enzyme System/metabolism
3.
JCI Insight ; 9(7)2024 Apr 08.
Article in English | MEDLINE | ID: mdl-38587080

ABSTRACT

BACKGROUNDAs Omicron is prompted to replicate in the upper airway, neutralizing antibodies (NAbs) delivered through inhalation might inhibit early-stage infection in the respiratory tract. Thus, elucidating the prophylactic efficacy of NAbs via nasal spray addresses an important clinical need.METHODSThe applicable potential of a nasal spray cocktail containing 2 NAbs was characterized by testing its neutralizing potency, synergetic neutralizing mechanism, emergency protective and therapeutic efficacy in a hamster model, and pharmacokinetics/pharmacodynamic (PK/PD) in human nasal cavity.RESULTSThe 2 NAbs displayed broad neutralizing efficacy against Omicron, and they could structurally compensate each other in blocking the Spike-ACE2 interaction. When administrated through the intranasal mucosal route, this cocktail demonstrated profound efficacy in the emergency prevention in hamsters challenged with authentic Omicron BA.1. The investigator-initiated trial in healthy volunteers confirmed the safety and the PK/PD of the NAb cocktail delivered via nasal spray. Nasal samples from the participants receiving 4 administrations over a course of 16 hours demonstrated potent neutralization against Omicron BA.5 in an ex vivo pseudovirus neutralization assay.CONCLUSIONThese results demonstrate that the NAb cocktail nasal spray provides a good basis for clinical prophylactic efficacy against Omicron infections.TRIAL REGISTRATIONwww.chictr.org.cn, ChiCTR2200066525.FUNDINGThe National Science and Technology Major Project (2017ZX10202203), the National Key Research and Development Program of China (2018YFA0507100), Guangzhou National Laboratory (SRPG22-015), Lingang Laboratory (LG202101-01-07), Science and Technology Commission of Shanghai Municipality (YDZX20213100001556), and the Emergency Project from the Science & Technology Commission of Chongqing (cstc2021jscx-fyzxX0001).


Subject(s)
Antibodies, Neutralizing , Nasal Sprays , Animals , Cricetinae , Humans , China , Trachea , Healthy Volunteers
4.
J Med Chem ; 67(5): 4007-4025, 2024 Mar 14.
Article in English | MEDLINE | ID: mdl-38381075

ABSTRACT

Invasive fungal infections pose a serious threat to public health and are associated with high mortality and incidence rates. The development of novel antifungal agents is urgently needed. Based on hit-to-lead optimization, a series of 2,4,6-trisubstituted triazine hydrazone compounds were designed, synthesized, and biological evaluation was performed, leading to the identification of compound 28 with excellent in vitro synergy (FICI range: 0.094-0.38) and improved monotherapy potency against fluconazole-resistant Candida albicans and Candida auris (MIC range: 1.0-16.0 µg/mL). Moreover, 28 exhibited broad-spectrum antifungal activity against multiple pathogenic strains. Furthermore, 28 could inhibit hyphal and biofilm formation, which may be related to its ability to disrupt the fungal cell wall. Additionally, 28 significantly reduced the CFU in a mouse model of disseminated infection with candidiasis at a dose of 10 mg/kg. Overall, the triazine-based hydrazone compound 28 with low cytotoxicity, hemolysis, and favorable ADME/T characteristics represents a promising lead to further investigation.


Subject(s)
Antifungal Agents , Candidiasis , Animals , Mice , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Microbial Sensitivity Tests , Fluconazole/pharmacology , Candida albicans , Candidiasis/drug therapy , Candidiasis/microbiology
5.
J Clin Transl Hepatol ; 12(2): 162-171, 2024 Feb 28.
Article in English | MEDLINE | ID: mdl-38343613

ABSTRACT

Background and Aims: SARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports. However, the safety and immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in patients with autoimmune liver diseases (AILD) is still unknown. Methods: Eighty-four patients with AILD were prospectively followed up after the second dose (primary) of inactivated SARS-CoV-2 vaccine. Some of them received the third dose (booster) of inactivated vaccine. Adverse events (AEs), autoimmune activation, and liver inflammation exacerbation after primary and booster vaccination were recorded. Meanwhile, dynamics of antireceptor-binding-domain IgG (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD-specific B cells responses were evaluated. Results: The overall AEs in AILD patients after primary and booster vaccination were 26.2% and 13.3%, respectively. The decrease of C3 level and increase of immunoglobulin light chain κ and λ levels were observed in AILD patients after primary vaccination, however, liver inflammation was not exacerbated, even after booster vaccination. Both the seroprevalence and titers of anti-RBD-IgG and NAbs were decreased over time in AILD patients after primary vaccination. Notably, the antibody titers were significantly elevated after booster vaccination (10-fold in anti-RBD-IgG and 7.4-fold in NAbs, respectively), which was as high as in healthy controls. Unfortunately, the inferior antibody response was not enhanced after booster vaccination in patients with immunosuppressants. Changes of atypical memory B cells were inversely related to antibody levels, which indicate that the impaired immune memory was partially restored partly by the booster vaccination. Conclusions: The well tolerability and enhanced humoral immune response of inactivated vaccine supports an additional booster vaccination in AILD patients without immunosuppressants.

7.
Eur J Med Chem ; 264: 116026, 2024 Jan 15.
Article in English | MEDLINE | ID: mdl-38070429

ABSTRACT

Here we designed and synthesized 58 deferasirox derivatives with the aim of discovering novel antifungal agents. Most compounds exhibited moderate to excellent in vitro antifungal activities against Cryptococcus neoformans H99 with MIC values ranging from 0.25 µg/mL to 16 µg/mL, including ten compounds with MIC values less than 1 µg/mL that were further screened against an additional six pathogenic fungi. This class of compounds showed high potency against Candida glabrata with MIC values ranging from <0.125 µg/mL to 1 µg/mL. We identified that compound 54 has high potency against 14 strains of Candida glabrata spp. and Cryptococcus spp. with MIC values ranging from <0.125 µg/mL to 1 µg/mL. In addition, compound 54 significantly reduced the CFU in a mouse model of disseminated infection with Cryptococcus neoformans H99 at a dose of 10 mg/kg, which is comparable to FLC. Further investigations on compound 54 are currently in progress.


Subject(s)
Cryptococcosis , Cryptococcus neoformans , Mice , Animals , Antifungal Agents/pharmacology , Deferasirox/pharmacology , Microbial Sensitivity Tests , Cryptococcosis/drug therapy
8.
J Med Chem ; 66(23): 16364-16376, 2023 12 14.
Article in English | MEDLINE | ID: mdl-37975824

ABSTRACT

Fungal pathogens can cause life-threatening infections, yet current antifungals are inadequate at treating many of these, highlighting the importance of novel drug discovery. Here, we report hit compound L14, a novel 8-hydroxyquinoline derivative with potent and broad-spectrum antifungal activity. In vitro experiments exhibited that L14 had better activity and lower cytotoxicity than that of clioquinol and showed synergy in combination with fluconazole (FLC). In a Candida albicans-infected murine model, L14 at 2 mg/kg showed better in vivo efficacy than clioquinol at reducing fungal burden and extending the survival of C. albicans-infected mice. In addition, L14 alone or in combination with FLC had significant inhibitory activity against hypha and biofilm formation. Overall, our data indicated that 8-hydroxyquinoline derivative L14 has favorable pharmacokinetics and acceptable safety profiles and could be further investigated as a promising antifungal hit compound.


Subject(s)
Candidiasis , Clioquinol , Animals , Mice , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Clioquinol/therapeutic use , Candidiasis/drug therapy , Candidiasis/microbiology , Microbial Sensitivity Tests , Drug Resistance, Fungal , Fluconazole/pharmacology , Candida albicans , Oxyquinoline/pharmacology , Oxyquinoline/therapeutic use , Drug Synergism
9.
Int J Med Sci ; 20(13): 1698-1704, 2023.
Article in English | MEDLINE | ID: mdl-37928876

ABSTRACT

Background: Conventional methods are low in positive rates and time-consuming for ascites pathogen detection in patients with end-stage liver disease (ESLD). With many advantages, metagenomic next-generation sequencing (mNGS) may be a good alternative method. However, the related studies are still lacking. Methods: Ascites from 50 ESLD patients were sampled for pathogen detection using mNGS and conventional methods (culture and polymorphonuclear neutrophils detection) in this prospective observational study. Results: Forty-two samples were detected positive using mNGS. 29 strains of bacteria, 11 strains of fungi, and 9 strains of viruses were detected. 46% of patients were detected to be co-infected with 2 or more pathogens by mNGS. Moreover, mNGS showed similar and high positive rates in ESLD patients with different clinical characteristics. Compared to conventional methods, mNGS had higher positivity rates (84% vs. 20%, P<0.001), sensitivity (45.2% vs. 23.8%, P=0.039), broader pathogen spectrum, shorter detection time (24 hours vs. 3-7 days), but lower specificity (25% vs 100%, P = 0.010). Furthermore, compared to conventional methods, mNGS showed similar consistence with final diagnosis (42% vs. 36%, P=0.539). Conclusions: mNGS may be a good supplement for conventional methods and helpful to early etiological diagnosis of peritonitis, and thus improve ESLD patients' survival.


Subject(s)
End Stage Liver Disease , Peritonitis , Humans , Ascites , High-Throughput Nucleotide Sequencing , Peritonitis/diagnosis , Peritonitis/etiology , Dietary Supplements , Sensitivity and Specificity
10.
Molecules ; 28(17)2023 Aug 30.
Article in English | MEDLINE | ID: mdl-37687172

ABSTRACT

Baicalein (BE), the major component of Scutellaria Baicalensis, exhibited potently antifungal activity against drug-resistant Candida albicans, and strong inhibition on biofilm formation. Therefore, a series of baicalein-core derivatives were designed and synthesized to find more potent compounds and investigate structure-activity relationship (SAR) and mode of action (MoA). Results demonstrate that A4 and B5 exert a more potent antifungal effect (MIC80 = 0.125 µg/mL) than BE (MIC80 = 4 µg/mL) when used in combination with fluconazole (FLC), while the MIC80 of FLC dropped from 128 µg/mL to 1 µg/mL. SAR analysis indicates that the presence of 5-OH is crucial for synergistic antifungal activities, while o-dihydroxyls and vic-trihydroxyls are an essential pharmacophore, whether they are located on the A ring or the B ring of flavonoids. The MoA demonstrated that these compounds exhibited potent antifungal effects by inhibiting hypha formation of C. albicans. However, sterol composition assay and enzymatic assay conducted in vitro indicated minimal impact of these compounds on sterol biosynthesis and Eno1. These findings were further confirmed by the results of the in-silico assay, which assessed the stability of the complexes. Moreover, the inhibition of hypha of this kind of compound could be attributed to their effect on the catalytic subunit of 1,3-ß-d-glucan synthase, 1,3-ß-d-glucan-UDP glucosyltransferase and glycosyl-phosphatidylinositol protein, rather than inhibiting ergosterol biosynthesis and Eno1 activity by Induced-Fit Docking and Molecular Dynamics Simulations. This study presents potential antifungal agents with synergistic effects that can effectively inhibit hypha formation. It also provides new insights into the MoA.


Subject(s)
Antifungal Agents , Flavanones , Antifungal Agents/pharmacology , Flavanones/pharmacology , Flavonoids , Biological Assay , Candida albicans
11.
Hum Vaccin Immunother ; 19(2): 2258567, 2023 08.
Article in English | MEDLINE | ID: mdl-37728115

ABSTRACT

Currently, the relationship between nutritional indices and the prognosis of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) remains unclear. This study aims to investigate the prognostic value of psoas muscle index (PMI), prognostic nutritional index (PNI), body mass index (BMI), and geriatric nutritional risk index (GNRI) in HCC patients treated with ICIs combined with TKIs. A total of 124 male patients with HCC were included in this study. PNI, PMI, BMI, and GNRI were calculated at the beginning of treatment. The Cox proportional hazards model was used to analyze the effect of various variables. In the univariate analysis, PMI, PNI, GNRI, and ALB were found to impact the outcomes of the patients at different follow-up times. However, the predictive value of these nutritional indices was eliminated when established risk factors were considered. In the multivariate analysis that only included nutrition-related indicators, PMI emerged as an independent prognostic factor for 1-year treatment outcomes. The group with low PMI (≤5.5409 cm2/m2) was found to have a higher risk of death at one year and at the end of the follow-up period.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Humans , Male , Aged , Prognosis , Immune Checkpoint Inhibitors/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Psoas Muscles/diagnostic imaging , Liver Neoplasms/drug therapy
12.
Entropy (Basel) ; 25(8)2023 Aug 02.
Article in English | MEDLINE | ID: mdl-37628190

ABSTRACT

Accurately predicting severe accident data in nuclear power plants is of utmost importance for ensuring their safety and reliability. However, existing methods often lack interpretability, thereby limiting their utility in decision making. In this paper, we present an interpretable framework, called GRUS, for forecasting severe accident data in nuclear power plants. Our approach combines the GRU model with SHAP analysis, enabling accurate predictions and offering valuable insights into the underlying mechanisms. To begin, we preprocess the data and extract temporal features. Subsequently, we employ the GRU model to generate preliminary predictions. To enhance the interpretability of our framework, we leverage SHAP analysis to assess the contributions of different features and develop a deeper understanding of their impact on the predictions. Finally, we retrain the GRU model using the selected dataset. Through extensive experimentation utilizing breach data from MSLB accidents and LOCAs, we demonstrate the superior performance of our GRUS framework compared to the mainstream GRU, LSTM, and ARIMAX models. Our framework effectively forecasts trends in core parameters during severe accidents, thereby bolstering decision-making capabilities and enabling more effective emergency response strategies in nuclear power plants.

13.
J Enzyme Inhib Med Chem ; 38(1): 2244696, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37553905

ABSTRACT

A series of novel triazole derivatives containing aryl-propanamide side chains was designed and synthesised. In vitro antifungal activity studies demonstrated that most of the compounds inhibited the growth of six human pathogenic fungi. In particular, parts of phenyl-propionamide-containing compounds had excellent, broad-spectrum antifungal activity against Candida albicans SC5314, Cryptococcus neoformans 22-21, Candida glabrata 537 and Candida parapsilosis 22-20 with MIC values in the range of ≤0.125 µg/mL-4.0 µg/mL. In addition, compounds A1, A2, A6, A12 and A15 showed inhibitory activities against fluconazole-resistant Candida albicans and Candida auris. Preliminary structure-activity relationships (SARs) are also summarised. Moreover, GC-MS analysis demonstrated that A1, A3, and A9 interfered with the C. albicans ergosterol biosynthesis pathway by inhibiting Cyp51. Molecular docking studies elucidated the binding modes of A3 and A9 with Cyp51. These compounds with low haemolytic activity and favourable ADME/T properties are promising for the development of novel antifungal agents.


Subject(s)
Antifungal Agents , Triazoles , Humans , Antifungal Agents/chemistry , Triazoles/chemistry , Molecular Docking Simulation , Fluconazole/pharmacology , Candida albicans , Structure-Activity Relationship , Microbial Sensitivity Tests
14.
Front Cell Infect Microbiol ; 13: 1151899, 2023.
Article in English | MEDLINE | ID: mdl-37396307

ABSTRACT

Introduction: The clinical significance of persistent positive in Hepatitis B Virus (HBV) DNA level in patients receiving antiviral therapy is not well known. We investigated factors associated with persistent viremia (PV) in patients with chronic hepatitis B (CHB) given 78-week entecavir. Methods: A total of 394 treatment-naïve CHB patients who had undergone liver biopsy at baseline and week 78 of treatment were analyzed in this prospective multicentre study. We identified patients with PV (above the lower limit of quantification, 20 IU/ml) after 78 weeks of entecavir therapy. Stepwise, forward, multivariate regression analyses of specified baseline parameters were apllied to identify factors associated with PV. Futhermore, we assessed the incidence of hepatocellular carcinoma (HCC) in all patients using models of the risk of HCC development. Results: Of the 394 patients, 90 (22.8%) still with PV after 78-week antiviral treatment. Factors associated significantly with PV (vs complete virological response, CVR) were HBV DNA level ≥8 log10 IU/mL (OR, 3.727; 95% CI, 1.851-7.505; P < 0.001), Anti-HBc level < 3 log10 IU/mL (OR, 2.384; 95% CI, 1.223-4.645; P=0.011), and HBeAg seropositivity (OR, 2.871; 95% CI, 1.563-5.272; P < 0.001). Patients with PV were less likely to have fibrosis progression and HCC development than those with the CVR. Of the 11 HBeAg-positive patients with HBV DNA level ≥8 log10 IU/mL and Anti-HBc level < 3 log10 IU/mL at baseline, 9 (81.8%) had persistent positivity in HBV DNA level and 0 had fibrosis progression at week 78 of treatment. Discussion: In conclusion, HBV DNA level ≥8 log10 IU/mL, Anti-HBc level < 3 log10 IU/mL and HBeAg seropositivity at baseline contribute to PV in patients with CHB receiving 78-week antiviral treatment. In addition, the rate of fibrosis progression and the risk of HCC development in patients with PV were kept low. The complete protocol for the clinical trial has been registered at clinicaltrials.gov (NCT01962155 and NCT03568578).


Subject(s)
Carcinoma, Hepatocellular , Hepatitis B, Chronic , Liver Neoplasms , Humans , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/drug therapy , DNA, Viral , Hepatitis B e Antigens/therapeutic use , Carcinoma, Hepatocellular/epidemiology , Prospective Studies , Treatment Outcome , Liver Neoplasms/epidemiology , Antiviral Agents/therapeutic use , Fibrosis , Hepatitis B virus/genetics
15.
Org Biomol Chem ; 21(28): 5840-5854, 2023 Jul 19.
Article in English | MEDLINE | ID: mdl-37401668

ABSTRACT

Quinone methides (QMs) are formed as the intermediates during lignin biosynthesis and chemical transformation; the chemical structure of the resulting lignin can then be significantly modified via the corresponding aromatization. Herein, the structure-reactivity relationship of ß-O-4-aryl ether QMs (GS-QM, GG-QM and GH-QM, which are 3-monomethoxylated QMs carrying syringyl, guaiacyl and p-hydroxyphenyl ß-etherified aromatic rings, respectively) was investigated to clarify the formation of alkyl-O-alkyl ether structures in lignin. The structural features of these QMs were characterized by NMR spectroscopy, and their alcohol-addition experiment was well performed at 25 °C to generate alkyl-O-alkyl/ß-O-4 products. The preferential conformation of GS-QM contains a stable directional intramolecular H-bond between γ-OH hydrogen and ß-phenoxy oxygen, which makes the ß-phenoxy group locate on the same side with γ-OH. In contrast, the ß-phenoxy groups in both GG- and GH-QM conformations are distant from the γ-OH; thus, the stable intermolecular H-bond is associated with the γ-OH hydrogen. Based on UV spectroscopy, the addition of methanol and ethanol occurs in QMs with a half-life of 1.7-2.1 and 12.8-19.3 minutes, respectively. With the same nucleophile, these QMs react faster in the order GH-QM > GG-QM > GS-QM. However, the reaction rate appears to be more influenced by the type of nucleophile than by the ß-etherified aromatic ring. Furthermore, the NMR spectra of products indicate that the steric bulkiness of both the ß-etherified aromatic ring and nucleophile contributes to the erythro-preferential formation of adducts from QMs. Moreover, the effect is more pronounced for the ß-etherified aromatic ring of QMs than the nucleophiles. The structure-reactivity relationship study demonstrates that the competition effect between H-bonds and steric hindrance determines the approaching direction and the accessibility of nucleophiles to planar QMs, resulting in stereo-differentiating formation of adducts. This model experiment may provide implications for the biosynthetic route and structural information of the alkyl-O-alkyl ether structure in lignin. Its results can also be further utilized to design innovative extraction methods of organosolv lignins for subsequent selective depolymerization or material preparation.

16.
Bioorg Chem ; 137: 106572, 2023 08.
Article in English | MEDLINE | ID: mdl-37156136

ABSTRACT

As a continuation study, 29 novel triazoles containing benzyloxy phenyl isoxazole side chain were designed and synthesized based on our previous work. The majority of the compounds exhibited high potency in vitro antifungal activities against eight pathogenic fungi. The most active compounds 13, 20 and 27 displayed outstanding antifungal activity with MIC values ranging from <0.008 µg/mL to 1 µg/mL, and showed potent activity against six drug-resistant Candida auris isolates. Growth curve assays further confirmed the high potency of these compounds. Moreover, compounds 13, 20 and 27 showed a potent inhibitory activity on biofilm formation of C. albicans SC5314 and C. neoformans H99. Notably, compound 13 showed no inhibition of human CYP1A2 and low inhibitory activity against CYP2D6 and CYP3A4, suggesting a low risk of drug-drug interactions. With high potency in vitro and in vivo and good safety profiles, compound 13 will be further investigated as a promising candidate.


Subject(s)
Antifungal Agents , Cryptococcus neoformans , Humans , Antifungal Agents/pharmacology , Antifungal Agents/chemistry , Triazoles/pharmacology , Triazoles/chemistry , Isoxazoles , Structure-Activity Relationship , Candida albicans , Microbial Sensitivity Tests
17.
J Med Virol ; 95(4): e28730, 2023 04.
Article in English | MEDLINE | ID: mdl-37185852

ABSTRACT

People living with HIV (PLWH) have poor outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); vaccination reduces the associated mortality. The humoral immune response dynamics after booster inactivated vaccinations in PLWH remain unclear. In this longitudinal observational study, 100 PLWH after primary inactivated SARS-CoV-2 vaccination were consecutively recruited and followed up. After booster vaccination (BV), neutralizing antibodies (NAbs) were detected at 1 month from all the PLWH, and the titer increased sixfold compared to that associated with the primary vaccination (PV), similar to that in healthy controls after BV. The NAbs titer declined over time after BV, but remained higher at 6 months than after PV. The NAbs response was elevated after BV with CD4 count <200 cells/µL, it was the poorest among the different CD4 cell count subgroups. Similar results were observed for anti-RBD-IgG responses. Moreover, RBD-specific MBCs were significantly elevated after BV in PLWH. No serious AEs were observed after BV in PLWH. In conclusion, booster inactivated SARS-CoV-2 vaccination is well tolerated and can elicit robust and durable humoral responses in PLWH. PLWH may benefit from a third dose of the inactivated vaccine.


Subject(s)
COVID-19 , HIV Infections , Humans , COVID-19/prevention & control , COVID-19 Vaccines , SARS-CoV-2 , Antibodies, Neutralizing , Vaccination , Antibodies, Viral
18.
Eur J Med Chem ; 257: 115506, 2023 Sep 05.
Article in English | MEDLINE | ID: mdl-37216811

ABSTRACT

Previous work led to the rational design, synthesis and testing of novel antifungal triazole analogues bearing alkynyl-methoxyl side chains. Tests of in vitro antifungal activity showed Candida albicans SC5314 and Candida glabrata 537 gave MIC values of ≤0.125 µg/mL for most of the compounds. Among these, compounds 16, 18, and 29 displayed broad-spectrum antifungal activity against seven human pathogenic fungal species, two fluconazole-resistant C. albicans isolates and two multi-drug resistant Candida auris isolates. Moreover, 0.5 µg/mL of 16, 18, and 29 was more effective than 2 µg/mL of fluconazole at inhibiting fungal growth of the strains tested. The most active compound (16) completely inhibited the growth of C. albicans SC5314 at 16 µg/mL for 24 h, affected biofilm formation and destroyed the mature biofilm at 64 µg/mL. Several Saccharomyces cerevisiae strains, overexpressing recombinant Cyp51s or drug efflux pumps, indicated 16, 18, and 29 targeted Cyp51 without being significantly affected by a common active site mutation, but were susceptible to target overexpression and efflux by both MFS and ABC transporters. GC-MS analysis demonstrated that 16, 18, and 29 interfered with the C. albicans ergosterol biosynthesis pathway by inhibition at Cyp51. Molecular docking studies elucidated the binding modes of 18 with Cyp51. The compounds showed low cytotoxicity, low hemolytic activity and favorable ADMT properties. Importantly, compound 16 showed potent in vivo antifungal efficacy in the G. mellonella infection model. Taken together, this study presents more effective, broad-spectrum, low toxicity triazole analogues that can contribute to the development of novel antifungal agents and help overcome antifungal resistance.


Subject(s)
Antifungal Agents , Triazoles , Humans , Antifungal Agents/pharmacology , Triazoles/pharmacology , Fluconazole/pharmacology , Molecular Docking Simulation , Microbial Sensitivity Tests , Candida albicans , Drug Resistance, Fungal , Saccharomyces cerevisiae
19.
RSC Adv ; 13(19): 12670-12676, 2023 Apr 24.
Article in English | MEDLINE | ID: mdl-37101526

ABSTRACT

Synergism between hierarchical zeolites and alumina in the preparation of active Mo catalysts, as a function of composition ratios, has been demonstrated in the cross-metathesis reaction between ethene and 2-butene. The metathesis reaction activity, reflected by ethene conversion, increases from 24.1% to 49.2% with the increase in the alumina content in composites from 10 wt% to 30 wt%. A further increase in the alumina content leads to the reduction in the metathesis activity, in which the ethene conversion decreases from 30.3% to 4.8% upon the enhanced alumina content from 50 wt% to 90 wt%. The impact of alumina content on the metathesis activity is closely associated with the interaction mode between the hierarchical ZSM-5 zeolite and alumina. TEM observation as well as EDS analysis and XPS results prove the progressive coating of alumina phase on the surface of zeolites along with the progressive enhancement of alumina content. The moderate alumina content in the composite enables the desired interaction between hierarchical zeolites and alumina, which is beneficial for the preparation of active catalysts for the alkene cross-metathesis reaction.

20.
Insects ; 14(4)2023 Apr 12.
Article in English | MEDLINE | ID: mdl-37103194

ABSTRACT

Chrysolina aeruginosa is a major pest of Artemisia ordosica, and knowledge of the spatial distribution pattern of its larvae in their natural habitat is crucial for the implementation of effective control measures. This study employed geostatistical methods to investigate the damage caused by larvae of different age groups and their spatial distribution pattern. The distribution of C. aeruginosa larvae, which cause damage to A. ordosica, differed significantly according to their age. Younger larvae were predominantly found in the middle and upper parts of the plant, whereas older larvae were mainly distributed in the middle and lower parts, with significant differences in distribution location. A generalized linear model analysis revealed that the height of the plant, and plant morphological characteristics such as height, crown width, and ground diameter were significantly correlated with the number of larvae present. Furthermore, the interaction of age with other variables had an impact on the number of larvae. Kriging interpolation showed that C. aeruginosa larvae were distributed in aggregated patches with strong spatial heterogeneity. The younger larvae were more abundant in the center of the sample site, while the older larvae tended to be distributed toward the edges. These findings provide valuable information for designing effective control programs.

SELECTION OF CITATIONS
SEARCH DETAIL
...